Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced its results for the first quarter of FY-2015.
The results shows EPS went stable at -$0.06 YoY, whereas Cash assets were reduced from $ 57.289 Million to $ 49.987 Million.
View the full earnings release here.